Sophie Postel-Vinay

Sophie Postel-Vinay is a French physician and scientist at the Institut Gustave Roussy where she has led an ATIP-Avenir team since 2018. She works on oncology and the development of new drugs and is an expert in early clinical trials. She was the 2019 winner of the Irène Joliot-Curie Prize in the “young woman scientist” category. Provided by Wikipedia
Showing 1 - 8 results of 8 for search 'Sophie Postel-Vinay', query time: 2.02s Refine Results
  1. 1
    Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments

    Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments by Carine Ngo, Sophie Postel-Vinay

    Published 2022-03-01
    Get full text
    Article
  2. 2
    Beyond DNA repair: the novel immunological potential of PARP inhibitors

    Beyond DNA repair: the novel immunological potential of PARP inhibitors by Roman M. Chabanon, Jean-Charles Soria, Christopher J. Lord, Sophie Postel-Vinay

    Published 2019-03-01
    Get full text
    Article
  3. 3
    A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials.

    A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. by Emmanuelle Kempf, Nathalie Lemoine, Gabrielle Tergemina-Clain, Anthony Turpin, Sophie Postel-Vinay, Emilie Lanoy, Jean-Charles Soria, Christophe Massard, Antoine Hollebecque

    Published 2016-01-01
    Get full text
    Article
  4. 4
    Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA

    Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA by Clémence Astier, Carine Ngo, Léo Colmet-Daage, Virginie Marty, Olivia Bawa, Claudio Nicotra, Maud Ngo-Camus, Antoine Italiano, Christophe Massard, Jean-Yves Scoazec, Cristina Smolenschi, Michel Ducreux, Antoine Hollebecque, Sophie Postel-Vinay

    Published 2024-01-01
    Get full text
    Article
  5. 5
    BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial

    BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial by John Hilton, Mihaela Cristea, Sophie Postel-Vinay, Capucine Baldini, Mark Voskoboynik, William Edenfield, Geoffrey I. Shapiro, Michael L. Cheng, Jacqueline Vuky, Bradley Corr, Sharmila Das, Abraham Apfel, Ke Xu, Martin Kozicki, Keziban Ünsal-Kaçmaz, Amy Hammell, Guan Wang, Palanikumar Ravindran, Georgia Kollia, Oriana Esposito, Shodeinde Coker, Jennifer R. Diamond

    Published 2022-08-01
    Get full text
    Article
  6. 6
    Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

    Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines by James Campbell, Colm J. Ryan, Rachel Brough, Ilirjana Bajrami, Helen N. Pemberton, Irene Y. Chong, Sara Costa-Cabral, Jessica Frankum, Aditi Gulati, Harriet Holme, Rowan Miller, Sophie Postel-Vinay, Rumana Rafiq, Wenbin Wei, Chris T. Williamson, David A. Quigley, Joe Tym, Bissan Al-Lazikani, Timothy Fenton, Rachael Natrajan, Sandra J. Strauss, Alan Ashworth, Christopher J. Lord

    Published 2016-03-01
    Get full text
    Article
  7. 7
    Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

    Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers by Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle

    Published 2022-07-01
    Get full text
    Article
  8. 8
    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore

    Published 2023-03-01
    Get full text
    Article

Search Tools: